Meeting
2018 Gastrointestinal Cancers Symposium
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/ leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
Authors
Teresa Mercade Macarulla
Vall d’Hebron University Hospital Institute of Oncology, Barcelona, Spain
Teresa Mercade Macarulla , Jens T. Siveke , Andrew Peter Dean , Richard Hubner , Jean-Frédéric Blanc , David Cunningham , Li-Tzong Chen , Beloo Mirakhur , Jie Chen , Floris A de Jong , Andrea Wang-Gillam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01494506
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 379)
DOI
10.1200/JCO.2018.36.4_suppl.379
Abstract #
379
Poster Bd #
H16
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI‑1: A phase III study of liposomal irinotecan (nal‑IRI)±5‑fluorouracil/leucovorin (5‑FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
First Author: Jens T. Siveke
Poster
2018 Gastrointestinal Cancers Symposium
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal‑IRI)±5‑fluorouracil/leucovorin (5‑FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.
First Author: Teresa Mercade Macarulla
Poster
2021 Gastrointestinal Cancers Symposium
Real-world one-year overall survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan in the NAPOLI-1 based regimen.
First Author: George P. Kim
Poster
2020 ASCO Virtual Scientific Program
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
First Author: Zev A. Wainberg